Integrating Blood Pressure Control With Multi-Class Kidney Protective Agents in Diabetic Kidney Disease
Electrolytes & Blood Pressure · 2026 · 24 (2) · 95
DOI: 10.5049/ebp.2026.24.e6 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Electrolytes & Blood Pressure, 2026. Verfasst von Hyoungnae Kim. Beteiligte Einrichtung: Division of Nephrology, Department of Internal Medicine, Soonchunhyang University Seoul Hospital, Seoul, Republic of Korea. Die Arbeit nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Diabetic kidney disease (DKD) remains a leading cause of chronic kidney disease progression and cardiovascular morbidity and mortality. Blood pressure (BP) control is a cornerstone of risk reduction in DKD, yet its management has become increasingly complex with the emergence of multi-class kidney-protective agents. Traditionally centered on renin-angiotensin-aldosterone system (RAAS) blockade with additional antihypertensive agents, contemporary treatment now incorporates sodium-glucose cotransporter-2 (SGLT2) inhibitors, non-steroidal mineralocorticoid receptor antagonists, and incretin-based therapies. Recent trials evaluating intensive systolic BP targets have demonstrated cardiovascular benefit in selected high-risk populations; however, the balance between benefit and kidney-related harm remains relevant in DKD. While RAAS blockade provides meaningful BP reduction and renoprotection, SGLT2 inhibitors, finerenone, and incretin-based therapies confer modest but clinically relevant BP lowering alongside substantial cardiorenal benefits through complementary mechanisms. Although these agents are not primarily used for antihypertensive intensification, their meaningful BP-lowering effects can influence overall BP control in routine practice. Although combination therapy appears biologically plausible and may enhance overall cardio-kidney-metabolic protection, definitive evidence supporting optimal sequencing, parallel initiation, or superiority in hard clinical outcomes remains limited. A pragmatic, individualized approach integrating disease-modifying therapies with conventional antihypertensive agents is therefore warranted. Future dedicated trials are needed to clarify optimal integration strategies to achieve safe BP control while maximizing long-term kidney and cardiovascular protection in DKD.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Nephrology, Department of Internal Medicine, Soonchunhyang University Seoul Hospital, Seoul, Republic of Korea.
ORCID-Profile: Hyoungnae Kim
Zitieren
APA
Kim, H. (2026). Integrating Blood Pressure Control With Multi-Class Kidney Protective Agents in Diabetic Kidney Disease. Electrolytes & Blood Pressure, 24(2), 95. https://doi.org/10.5049/ebp.2026.24.e6
Vancouver
Kim H. Integrating Blood Pressure Control With Multi-Class Kidney Protective Agents in Diabetic Kidney Disease. Electrolytes & Blood Pressure. 2026;24(2):95. doi:10.5049/ebp.2026.24.e6
BibTeX
@article{Kim2026,
author = {Kim, Hyoungnae},
title = {Integrating Blood Pressure Control With Multi-Class Kidney Protective Agents in Diabetic Kidney Disease},
journal = {Electrolytes & Blood Pressure},
year = {2026},
volume = {24},
number = {2},
pages = {95},
doi = {10.5049/ebp.2026.24.e6}
}
EUVIMED